SMS Pharmaceuticals has informed that Board of Directors of the Company at their meeting held on today considered and approved the: Standalone and Consolidated Un-audited Financial Results for the Quarter ended 30th June, 2021 along with the Limited Review Report, Reclassification of promoter group shareholding from promoter category to public category, Directors Report by the Board for the FY 2020-21, Convening the 33rd Annual General Meeting on 30th, September, 2021 and Dividend Distribution Policy. Accordingly, the company has enclosed the following: Reclassification of Promoter group shareholding from promoter category to public category and Standalone and Consolidated un-audited Financial Results for the quarter ended 30th June, 2021 along with the Limited Review Report. The meeting commenced at 10.30 am and concluded at 12.30 pm.
The above information is a part of company’s filings submitted to BSE.
